Abstract
Body composition phenotypes may reflect aspects of patients (pts)’ immunology and thereby their ability to respond to immunotherapies. Therefore, our study aimed to describe the pre-treatment body composition profile of pts and explore the possible associations between these parameters and clinical outcomes in non-small-cell lung cancer (NSCLC) pts receiving first-line Pembrolizumab monotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
